Skip to main content
AZTA
NASDAQ Technology

Azenta 10-K: $149M Goodwill Impairment, Adverse ICFR Opinion, $167M Net Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$47.09
Mkt Cap
$1.966B
52W Low
$15.93
52W High
$50.055
52W Position info
196% above low
Off High info
5.9% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AZTA has more than doubled off its 52-week low of $15.93.

Summary

Azenta's fiscal 2026 10-K shows a $149.1 million non-cash goodwill impairment driving a $167.0 million net loss, and an unremediated account-reconciliation material weakness that drew an adverse auditor opinion on internal controls. Revenue rose 4.7% to $621.7 million, with $506.4 million of cash and securities and no debt.


Key Events · Earnings and Guidance · AZTA

  • Full-Year Revenue $621.7 Million

    Fiscal 2026 revenue rose 4.7% to $621.703 million from $593.821 million, with SMS up 6.1% to $344.443 million and Multiomics up 3.0% to $277.260 million.

  • $149.1 Million Goodwill Impairment

    A non-cash impairment of $149.083 million ($112.4 million Multiomics, $36.6 million SMS) drove the operating loss to $174.699 million and net loss to $166.985 million, or -$3.70 per diluted share.

  • Adverse Internal-Control Opinion

    PwC issued an adverse opinion on ICFR as of September 30, 2026; the account-reconciliation material weakness identified in the March 2025 quarter remains unremediated and caused immaterial misstatements in fiscal 2025 and 2026 interim and annual statements.

  • Balance Sheet and Buyback

    Cash, equivalents and restricted cash of $198.3 million plus $308.1 million of marketable securities, no outstanding debt; 4.4 million shares repurchased for $118.2 million in fiscal 2026, with $131.8 million remaining under the 2025 program.


Analysis · AZTA · Technology

The investment case turns on two items in Azenta's fiscal 2026 annual report: a $149.1 million non-cash goodwill impairment that drove a $167.0 million net loss and a $174.7 million operating loss, versus a $26.8 million operating loss a year earlier, and an adverse opinion on internal control over financial reporting from PricewaterhouseCoopers. The account-reconciliation material weakness first identified in the March 2025 quarter is still unremediated as of September 30, 2026, and management concluded disclosure controls were not effective. That keeps a governance overhang on the stock and raises the risk of delayed or restated reporting. The balance sheet is the offset: $198.3 million of cash and restricted cash plus $308.1 million of marketable securities and no debt. During the year the company bought back 4.4 million shares for $118.2 million, with $131.8 million left on the authorization. Revenue grew 4.7% to $621.7 million, but gross margin slipped to 44.2% on weak Automated Stores volumes and Sanger sequencing declines, the same pressures behind the October 5 Multiomics restructuring.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AZTA was trading at $47.09 on NASDAQ in the Technology sector, with a market capitalization of approximately $2B. The 52-week trading range was $15.93 to $50.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AZTA - Latest Insights

AZTA
Nov 10, 2026, 5:44 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $44.20
Real-time Price: $44.80 info
Change: +$0.600 (+1%) info
Market Cap: $1.879B info
AZTA
Nov 10, 2026, 4:30 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $39.99
Real-time Price: $44.80 info
Change: +$4.81 (+12%) info
Market Cap: $1.879B info
AZTA
Oct 30, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $39.87
Real-time Price: $44.80 info
Change: +$4.93 (+12%) info
Market Cap: $1.879B info
AZTA
Oct 07, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.04
Real-time Price: $44.80 info
Change: +$4.76 (+12%) info
Market Cap: $1.879B info
AZTA
Aug 24, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.90
Real-time Price: $44.80 info
Change: +$7.90 (+21%) info
Market Cap: $1.879B info